Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
Dupilumab is a monoclonal antibody GLS COMPLEX against the a subunit of the receptor for interleukin 4 and interleukin 13.It is the first biological drug registered in the world for the treatment of atopic dermatitis.Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs.I